Wednesday, December 20, 2023
7:00PM – 8:00PM ET
Please note this TeleECHO program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.
This educational program focuses on strategies to overcome resistance to endocrine therapy in early HR+/HER2- breast cancer. Through TeleECHO sessions, healthcare practitioners will develop a plan to help patients consistently and tolerably use oral anti-cancer medications for HR+/HER2- breast cancer. The program will analyze clinical trial data on CDK4/6 inhibitors in early HR+/HER2- breast cancer to optimize monitoring and managing treatment-associated adverse events. Additionally, healthcare practitioners will develop strategies to support patients in their adherence and persistence with agreed-upon treatment plan for HR+/HER2- early breast cancer.
|Sramila Aithal, MD
Alliance Cancer Specialists
US Oncology Network
This CME initiative is designed to meet the educational needs of medical oncologists, oncology nurses, pharmacists, nurse practitioners, physician assistants, and other oncology healthcare team providers involved in the treatment of patients with hormone receptor-positive, HER2-negative breast cancer.
Upon the completion of this program, attendees should be able to:
- Formulate a plan to support a patient’s consistent, chronic, and tolerable use of oral anti-cancer medications for HR+/HER2-negative breast cancer
- Critically analyze CDK 4/6 inhibitor clinical trials data in early HR+/HER2-negative breast cancer to optimize the monitoring and management of treatment-associated adverse events
- Develop strategies to support the patient’s adherence and persistence with agreed upon treatment for HR+/HER2-negative early breast cancer
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]